N
MNPR icon

Nuveen’s Monopar Therapeutics MNPR Stock Holding History

Nuveen’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$304K Hold
5,551
– – ﹤0.01% 3004
2025
Q4 		$362K Buy
5,551
+1,330
+32% +$109K ﹤0.01% 2992
2025
Q3 		$345K Buy
+4,221
New +$189K ﹤0.01% 3021

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Nuveen's MNPR Position: Q1 2026 in Review

Nuveen held its Monopar Therapeutics (MNPR) position steady in Q1 2026 at 5,551 shares worth $304K. The position accounts for ﹤0.01% of the portfolio, ranked #3004.

Nuveen first reported a position in MNPR in Q3 2025 and has held it in 3 quarters since. The position peaked at $362K in Q4 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Nuveen held 5,551 shares of Monopar Therapeutics worth $304K as of Q1 2026.
  • Nuveen left its Monopar Therapeutics share count unchanged in Q1 2026.
  • Monopar Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #3004 holding.
  • Nuveen first reported a position in Monopar Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Nuveen's Monopar Therapeutics position peaked at $362K in Q4 2025.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.